Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy (Q35138891)

6 August 2017

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy (English)

1 reference

6 August 2017

1 reference

1 reference

5

R Coombs

1 reference

6 August 2017

6

A C Collier

1 reference

6 August 2017

G F Vanhove

1

1 reference

6 August 2017

J M Gries

2

1 reference

6 August 2017

D Verotta

3

1 reference

6 August 2017

L B Sheiner

4

1 reference

6 August 2017

T F Blaschke

7

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 November 1997

1 reference

Antimicrobial Agents and Chemotherapy

6 August 2017

1 reference

6 August 2017

41

1 reference

6 August 2017

11

1 reference

6 August 2017

2433-2438

1 reference

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164141

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164141

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164141

Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164141

Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164141

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164141

Zidovudine response relationships in early human immunodeficiency virus infection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164141

Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=164141

Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9371346

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9371346

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

PMCID

164141

1 reference

6 August 2017

1 reference